Tech Company Financing Transactions
PepGen Funding Round
PepGen, based in Cambridge, secured $112.5 million from Adage Capital Management, CureDuchenne Ventures and Deerfield Capital.
Transaction Overview
Company Name
Announced On
8/6/2021
Transaction Type
Venture Equity
Amount
$112,500,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will be used to advance PepGen's lead programs: EDO51 for Duchenne muscular dystrophy (DMD), entering Phase 1 clinical trials in 2022, and EDODM1 for myotonic dystrophy type 1 (DM1), entering clinical trials in early 2023, as well as a large pipeline of additional oligonucleotide candidates.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
245 Main St. 2nd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Undisclosed
Website
Email Address
Overview
PepGen is harnessing the power of our Enhanced Delivery Oligonucleotide technology to solve the challenge of getting oligonucleotides to where they need to be to work, and to realize the clinical potential of oligonucleotide therapies to transform the lives of people living with neuromuscular diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James McArthur
Chief Medical Officer
Ramin Farzaneh-Far
Vice President
Sonia Bracegirdle
Vice President
Caroline Godfrey
VP - Finance
David Pelissier
VP - Manufacturing
Niels Svenstrup
Browse more venture capital transactions:
Prev: 8/6/2021: Messari venture capital transaction
Next: 8/6/2021: Cricket Health venture capital transaction
Share this article
About Our VC Transactions Data
We record every notable VC transaction. All VC database entries reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs